Member Info for liquid1

Link

http://bit.ly/2WcIhvk

Q4: Just looking forward, what key milestones should shareholders be looking out for over the next 12 months?

A4: Well, the very first one which I mentioned briefly there was the results of the open label extension study, we call it an extension study because the study is open to patients who participated in the Phase III study. So, we’ve got just over 60 patients in the study, we should be reporting those results within the next month, certainly by the end of June, so that’s the first piece of news.

As I alluded to, the two main parts of the company, certainly over the next 12 months, it maybe sooner, but we should be doing something very practically with the spin-out and then we’ll see where we get to with the interest with Lupuzor.

So, if you add all of that up, quite a lot of potentially positive news flow coming up.

What we are seeing is an awful lot of renewed interest in Lupuzor, we as a company are very much concentrated on the paths to market for Lupuzor so that’s both the development pathway and also the regulatory pathway.

With a lot of the data, obviously now being examined form that Phase III study, it’s showing us an awful lot of very good signs and that is what other people are seeing as well so we’ve had a number of discussions ongoing for a little while now. Those discussions are starting to come to fruition so we are expecting to see some movement in and around Lupuzor over the next few months so we’ll see where that gets us but it’s looking quite good at the moment.

https://www.*************.net/chairman-qa-with-tim-mccarthy-at-immupharma-plc-lonimm-3/

Q5: Today, an independent research outfit, The Life Sciences Division have issued an initiation note on ImmuPharma with a price target of 92p, can you give us some insight into their views behind this pretty bullish price target really?

A5: Yes, obviously it’s always nice to have a buy recommendation and a bullish price target which is frankly way above where we are, virtually 10p versus 92p price target but this is very much based on their own independent research.

A lot of the note concentrates on Lupuzor although there is comment on the technologies as well and what it’s focussing on is the differentiation that Lupuzor has against other drugs in development for Lupus.

Very much what I alluded to earlier that it’s a very safe drug which is quite unique in itself but the results that we did get from the Phase III are very encouraging especially when you look at it in targeted populations.

They’ve done, I think, a very very good job at analysing all that data and putting it in a context with the other drugs in development in this area which unfortunately for patients are not getting a very good run through, either because of associated safety or frankly lack of efficacy.

In that context, they’ve had a look at Lupuzor and its chances of getting through to the market and I think on that basis alone, that’s why they’re very positive and they’ve come up with a recommendation.

Very pleased to get that and I think, certainly in these days with post-MiFID which a lot of your listeners will be familiar with, it’s very difficult for small companies like us to get good independent research. That is what investors require otherwise they’re investing in companies blindly whereas 5/10 years ago, there was a lot more research available even for small companies.

So, to get something as well written as this I think is a real bonus for the company and its shareholders in turn.

With NEX Over 1p by tomorrow. All vote in today by 10.00am Pacific time GUN will be aware tomorrow of impending gift of Oyster Assets

Why don’t Motif ring the FDA and ask them: “What part of news within 30days do you not understand ?” FFS, FDA get your house in order!!!

Dakad Thanks for that info FDA are the problem! Why can’t they stick to their times.

According to CEO interview! So anytime before 10th June

Northbay and Gunsynd are currently in discussions with a third party to raise money for the Subco to progress further work on the Madagascar licence. We maintain our belief that this asset has great potential. This change in strategy will hopefully see that realised. Advancing this project is now a priority for Gunsynd alongside the Human Brands IPO. https://www.investegate.co.uk/gunsynd-plc--gun-/rns/half-year-report/201903151445320658T/

Oyster Confirms Good Quality Oil Source Rock in Madagascar

Tuesday, December 12, 2017 4:10 PM

VANCOUVER, BC / ACCESSWIRE / December 12, 2017 / Oyster Oil and Gas Ltd. ("Oyster" or the "Company") (TSX-V: OY, FSE: 13L) commissioned an independent geochemistry study by UK-based GH Geochem Ltd. of core samples recovered from a well drilled as part of the 4 well coring campaign carried out in Block 1101 in Q3/Q4 2014. The cores were recovered from a well drilled at Ankaramy, which is adjacent to some very large, highly prospective anticlinal structures located on the Ampasindava Peninsula, in the southwest of Block 1101.

In summary, the biomarker evaluation of the migrated oil not only confirms the presence of migrated petroleum but also shows that the oil is from a peak mature, clay-rich source rock deposited in a marine nearshore environment, probably migrated from more deeply buried Jurassic or perhaps older source rocks.

Dr. Phil Roach, Oyster's Head of Exploration, commented, "It has taken three years for Oyster to get access to these well cores and undertake this important piece of geochemical analysis work done, which confirms that there is a viable working petroleum system in this part of Madagascar."

https://www.accesswire.com/484161/Oyster-Confirms-Good-Quality-Oil-Source-Rock-in-Madagascar

https://m.youtube.com/watch?v=HLDuHK1h43o Oyster boss opens up about 'world-class' potential of its Djibouti and Madagascar assets 16:25 04 Dec 2017 Oyster Oil & Gas Ltd (CVE:OY) president and chief executive Michael Wood updates investors at the World Oil & Gas Week in London. He talks to Proactive's Andrew Scott about the "huge potential" of its two assets in Djibouti and Madagascar. "Both assets have the potential to make new world-class discoveries." Wood adds: "Arguably why I started Oyster was to get back into that block in Madagascar [where] we saw huge potential with map structures that are measuring potentially into tens of billions of barrels https://www.proactiveinvestors.co.uk/companies/stocktube/8479/oyster-boss-opens-up-about-world-class-potential-of-its-djibouti-and-madagascar-assets-8479.html

Gunsynd Could Acquire Oyster Oil & Gas Subsidiary In Loan Settlement LONDON (Alliance News) - Natural resources investor Gunsynd PLC said Monday it has reached a debt ...
Alliance News4 March, 2019 | 4:24PMEmail Form
LONDON (Alliance News) - Natural resources investor Gunsynd PLC said Monday it has reached a debt settlement agreement with Oyster Oil & Gas Ltd.
Shares in Gunsynd were up 38% at 0.029 pence on Monday.
Gunsynd invested GBP250,000 in Oyster, by way of a convertible loan, in July 2017.
Along with Northbay Capital Partners Corp, Gunsynd has reached a conditional agreement with Oyster to settle the total debt of CAD1.4 million - around GBP812,600 - owed to them by Oyster.
Under the agreement, Oyster's debt will be settled in exchange for the entire outstanding share capital of an Oyster subsidiary - also called Oyster Oil & Gas Ltd. The subsidiary holds Oyster's production sharing contracts in Madagascar and Djibouti.
Oyster's shareholders would need to approve the deal, as will the TSX Ventire Exchange.
The board of the Oyster subsidiary is still under discussion with an announcement to follow "in due course".
Alongside the convertible loan note, Gunsynd also has 2.3 million Oyster shares or a 5.3% stake.
By Anna Farley; annafarley@alliancenews.com

Northbay and Gunsynd are currently in discussions with a third party to raise money for the Subco to progress further work on the Madagascar licence. We maintain our belief that this asset has great potential. This change in strategy will hopefully see that realised. Advancing this project is now a priority for Gunsynd alongside the Human Brands IPO. https://www.investegate.co.uk/gunsynd-plc--gun-/rns/half-year-report/201903151445320658T/

Oyster boss opens up about 'world-class' potential of its Djibouti and Madagascar assets Share 16:25 04 Dec 2017 Oyster Oil & Gas Ltd (CVE:OY) president and chief executive Michael Wood updates investors at the World Oil & Gas Week in London. He talks to Proactive's Andrew Scott about the "huge potential" of its two assets in Djibouti and Madagascar. "Both assets have the potential to make new world-class discoveries." Wood adds: "Arguably why I started Oyster was to get back into that block in Madagascar [where] we saw huge potential with map structures that are measuring potentially into tens of billions of barrels https://www.proactiveinvestors.co.uk/companies/stocktube/8479/oyster-boss-opens-up-about-world-class-potential-of-its-djibouti-and-madagascar-assets-8479.html

Shinju Highlights

First container landed November 2018. Soft launch into MD/DC and Florida. 100 new accounts (75 in MD/DC, 25 in Florida) in first 90 days

Launched into NY on April 1st

Launched into Las Vegas April 15th

Launched into Thailand in December 2018

2019 planned distribution will take brand to NJ, PA, NC, WV, VA, TX, AZ, CA, Mexico, Hong Kong, Canada and United Kingdom.

Flagship Bloomingdales location (5th Avenue, NYC) added brand to menu Q1 2019

Featured at New York City Fashion Week Q1 2019

Costco launch Q2/Q3 2019

Total Wine in Q2/Q3 2019

https://www.shinjuspirits.com/

Don’t forget Human Brands: Costco USA

Human Brands' first container of Shinju arrived in the US in November 2018. Human Brands planned a soft launch into two of its key markets, Washington DC/Maryland and Fort Lauderdale, Florida. In just those two markets, with minimal sales and marketing support, Human Brands sold approximately 300 cases of Shinju. A US distributor, Oak Beverage, will launch Shinju into the New York market starting on1 April 2019. Oak Beverage has roughly 10,000 accounts throughout the State and plans to make Shinju its premier whisky brand in its portfolio. Shinju has been added to the menu at Bloomingdales' flagship location on 5(th) Avenue in New York City. The brand was also featured at New York City Fashion Week 2019. Fedway, New Jersey's second largest distributor, has committed to take on Shinju distribution.

Two major retailers have also committed to buying Shinju for 2019; Costco, one of the largest alcohol sellers in the US, and Total Wine, plan to start selling Shinju.

In the last half of 2018 Human Brands also focused on building its Mazeray division. Mazeray is Human Brands' division which sells Miolo, a premier Brazilian wine. Human Brands officially acquired Mazeray in March 2018 but did not take full operational control until July 2018. Since then, Human Brands has significantly grown the business. Mazeray was selling into a number of States in the US prior to the acquisition, but since then Human Brands has expanded the brand's distribution into several new States, including Maryland, Nevada, California, Texas, Arizona, Wisconsin and Tennessee.

Human Brands has also spent the past six months working to get ready for the 2019 launch of its flagship Tequila brand, Copa Imperial.

Human Brands is making good progress towards preparing for a proposed listing on the Standard Segment of the Main Market of the London Stock Exchange during 2019 Audits for 3 years prior to 2018 have now been completed and work has begun on the prospectus

https://www.humanbrandsinc.com/investors

Human Brands Group, is a diversified holding company in the premium spirit, wine and beer sector with a primary focus on distribution, brand development and strategic acquisitions in North America, Asia and the U.K/Western Europe.
?
The Company commenced operations in 2014 and at present operates within the United States and Asia, the largest and fastest growing beverage markets in the world. Our expansion capital is supporting new operations in Hong Kong, China and adding to our US distribution with 21 new states.

No quotes online

Thanks for that information!

Possible EDL type rise last month. EDL went up 500% last month! We’ll soon know on Friday